Amylin (AMLN) Shares Pop on New M&A Chatter (BMY) (AZN)
Tweet Send to a FriendGet Alerts AMLN Hot Sheet
Up)
Trade AMLN Now!
Shares of Amylin Pharmaceuticals (Nasdaq: AMLN) are over 10 percent higher Monday morning on further M&A chatter.
In February, Amylin ripped following news Bristol-Myers Squibb (NYSE: BMY) was looking to acquire the pharma in a $22 per share deal. Amylin rejected the offer in late March, but got a little pickup in April when reports surfaced that Bristol-Myers might still be interested in a deal.
The NY Times Monday is reporting Amylin is still in talks for a potential deal. Advisors hired include Credit Suisse, Goldman Sachs, and law firm Skadden, Arps, Slate, Meagher & Flom.
Amylin's key prospects include Type 2 diabetes drugs Bydureon and Byetta. In addition, activist investor Carl Icahn is "encouraging" Amylin to get acquired, else he might force the move in a proxy battle.
Reuters sees a potential buyer in AstraZeneca (NYSE: AZN), which just this morning announced its intention to acquire Ardea Biosciences (Nasdaq: RDEA) in a $1.26 billion deal. Astra is said to be looking at non-organic growth avenues to bolster its diabetes drugs following upcoming patent expiration.
Ahead of the bell, Amylin shares are about 11 percent better.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
In February, Amylin ripped following news Bristol-Myers Squibb (NYSE: BMY) was looking to acquire the pharma in a $22 per share deal. Amylin rejected the offer in late March, but got a little pickup in April when reports surfaced that Bristol-Myers might still be interested in a deal.
The NY Times Monday is reporting Amylin is still in talks for a potential deal. Advisors hired include Credit Suisse, Goldman Sachs, and law firm Skadden, Arps, Slate, Meagher & Flom.
Amylin's key prospects include Type 2 diabetes drugs Bydureon and Byetta. In addition, activist investor Carl Icahn is "encouraging" Amylin to get acquired, else he might force the move in a proxy battle.
Reuters sees a potential buyer in AstraZeneca (NYSE: AZN), which just this morning announced its intention to acquire Ardea Biosciences (Nasdaq: RDEA) in a $1.26 billion deal. Astra is said to be looking at non-organic growth avenues to bolster its diabetes drugs following upcoming patent expiration.
Ahead of the bell, Amylin shares are about 11 percent better.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- Can AMD (AMD) Shake Off the Goldman Downgrade?
- Websense (WBSN) Acquired by Vista Equity Partners for $24.75/Share
Create E-mail Alert Related Categories
Insiders' Blog, Mergers and AcquisitionsRelated Entities
Carl Icahn, Credit Suisse
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
